PT3140296T - Moduladores de gpr40 de pirrolidina para tratamento de doenças tais como diabetes - Google Patents

Moduladores de gpr40 de pirrolidina para tratamento de doenças tais como diabetes

Info

Publication number
PT3140296T
PT3140296T PT157230954T PT15723095T PT3140296T PT 3140296 T PT3140296 T PT 3140296T PT 157230954 T PT157230954 T PT 157230954T PT 15723095 T PT15723095 T PT 15723095T PT 3140296 T PT3140296 T PT 3140296T
Authority
PT
Portugal
Prior art keywords
diabetes
diseases
treatment
gpr40 modulators
pyrrolidine
Prior art date
Application number
PT157230954T
Other languages
English (en)
Portuguese (pt)
Inventor
A Jurica Elizabeth
Hong Zhenqiu
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of PT3140296T publication Critical patent/PT3140296T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PT157230954T 2014-05-07 2015-05-06 Moduladores de gpr40 de pirrolidina para tratamento de doenças tais como diabetes PT3140296T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461989651P 2014-05-07 2014-05-07

Publications (1)

Publication Number Publication Date
PT3140296T true PT3140296T (pt) 2018-06-27

Family

ID=53181359

Family Applications (1)

Application Number Title Priority Date Filing Date
PT157230954T PT3140296T (pt) 2014-05-07 2015-05-06 Moduladores de gpr40 de pirrolidina para tratamento de doenças tais como diabetes

Country Status (33)

Country Link
US (4) US9873679B2 (OSRAM)
EP (1) EP3140296B1 (OSRAM)
JP (1) JP6483156B2 (OSRAM)
KR (1) KR102336370B1 (OSRAM)
CN (1) CN106458976B (OSRAM)
AR (1) AR100328A1 (OSRAM)
AU (1) AU2015256120B2 (OSRAM)
BR (1) BR112016024936A2 (OSRAM)
CA (1) CA2948161C (OSRAM)
CL (1) CL2016002809A1 (OSRAM)
CY (1) CY1120340T1 (OSRAM)
DK (1) DK3140296T3 (OSRAM)
EA (1) EA033250B1 (OSRAM)
ES (1) ES2674531T3 (OSRAM)
HR (1) HRP20180641T1 (OSRAM)
HU (1) HUE039288T2 (OSRAM)
IL (1) IL248668B (OSRAM)
MA (1) MA39427B1 (OSRAM)
MX (1) MX378160B (OSRAM)
MY (1) MY181959A (OSRAM)
NZ (1) NZ727146A (OSRAM)
PE (1) PE20161363A1 (OSRAM)
PH (1) PH12016502034B1 (OSRAM)
PL (1) PL3140296T3 (OSRAM)
PT (1) PT3140296T (OSRAM)
RS (1) RS57170B1 (OSRAM)
SG (1) SG11201609170UA (OSRAM)
SI (1) SI3140296T1 (OSRAM)
SM (1) SMT201800342T1 (OSRAM)
TN (1) TN2016000444A1 (OSRAM)
TR (1) TR201809633T4 (OSRAM)
TW (1) TWI659951B (OSRAM)
WO (1) WO2015171722A1 (OSRAM)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016024936A2 (pt) * 2014-05-07 2017-08-15 Bristol Myers Squibb Co moduladores de gpr40 à base de pirrolidina para tratamento de doenças como diabetes
EP3140297B1 (en) * 2014-05-07 2018-04-11 Bristol-Myers Squibb Company Pyrrolidine gpr40 modulators for the treatment of diseases such as diabetes
CN110225752B (zh) 2016-09-12 2023-05-05 整体健康 用作gpr120调节器的单环化合物
CA3041038A1 (en) 2016-09-12 2018-03-15 Numerate, Inc. Bicyclic compounds useful as gpr120 modulators
CN110719903A (zh) * 2017-03-31 2020-01-21 武田药品工业株式会社 芳族环化合物
CN110694071B (zh) * 2017-08-21 2020-09-22 武汉大学 Gpr31抑制剂在制备治疗心肌肥厚及相关疾病药物中的应用
JP7062792B2 (ja) 2018-02-13 2022-05-06 ギリアード サイエンシーズ, インコーポレイテッド Pd-1/pd-l1阻害剤
EP3781556B1 (en) 2018-04-19 2025-06-18 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
CN118221646A (zh) 2018-07-13 2024-06-21 吉利德科学公司 Pd-1/pd-l1抑制剂
KR102635333B1 (ko) 2018-10-24 2024-02-15 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
JP2024522718A (ja) 2021-06-16 2024-06-21 セルジーン コーポレーション 神経変性疾患の治療のための、カルボン酸基を含むアゼチジニル化合物
CN116283699B (zh) * 2023-03-02 2025-02-11 遵义医科大学 一种合成氟烷基取代的吡咯烷的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614492A (en) 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
AU2010303670A1 (en) 2009-10-06 2012-03-29 Bristol-Myers Squibb Company Pyrrolidine GPR40 modulators
US7939569B1 (en) * 2009-12-01 2011-05-10 Hoffmann-La Roche Inc. Aniline analogs as glycogen synthase activators
GB2498976A (en) * 2012-02-01 2013-08-07 Prosidion Ltd GPR119 agonists useful in the treatment of type II diabetes
US9120798B2 (en) 2012-08-01 2015-09-01 Bristol-Myers Squibb Company Amino-heteroaryl 7-hydroxy-spiropiperidine indolinyl antagonists of P2Y1 receptor
CA2891569A1 (en) * 2012-11-16 2014-05-22 Bristol-Myers Squibb Company Pyrrolidine gpr40 modulators
ES2606685T3 (es) * 2012-11-16 2017-03-27 Bristol-Myers Squibb Company Moduladores de dihidropirazol GPR40
MX2015005720A (es) 2012-11-16 2015-09-08 Bristol Myers Squibb Co Moduladores de dihidropirazol de receptor acoplado a la proteina g (gpr40).
ES2605856T3 (es) 2012-11-16 2017-03-16 Bristol-Myers Squibb Company Moduladores GPR40 de dihidropirazol
EP3140294A1 (en) 2014-05-07 2017-03-15 Bristol-Myers Squibb Company Pyrrolidine gpr40 modulators
ES2747808T3 (es) 2014-05-07 2020-03-11 Croma Pharma Ges M B H Solución oftálmica acuosa y método para tratar el síndrome del ojo seco
BR112016024936A2 (pt) * 2014-05-07 2017-08-15 Bristol Myers Squibb Co moduladores de gpr40 à base de pirrolidina para tratamento de doenças como diabetes

Also Published As

Publication number Publication date
CA2948161C (en) 2020-10-27
JP2017514856A (ja) 2017-06-08
US20150322044A1 (en) 2015-11-12
HUE039288T2 (hu) 2018-12-28
WO2015171722A1 (en) 2015-11-12
KR102336370B1 (ko) 2021-12-06
SI3140296T1 (en) 2018-06-29
AU2015256120B2 (en) 2019-03-28
NZ727146A (en) 2020-01-31
JP6483156B2 (ja) 2019-03-13
PH12016502034A1 (en) 2017-01-09
BR112016024936A2 (pt) 2017-08-15
HRP20180641T1 (hr) 2018-06-01
CA2948161A1 (en) 2015-11-12
MY181959A (en) 2021-01-15
EP3140296B1 (en) 2018-04-11
US9873679B2 (en) 2018-01-23
AR100328A1 (es) 2016-09-28
US20200299267A1 (en) 2020-09-24
AU2015256120A1 (en) 2016-12-22
US20190112293A1 (en) 2019-04-18
MA39427A1 (fr) 2017-11-30
MX378160B (es) 2025-03-10
TWI659951B (zh) 2019-05-21
PL3140296T3 (pl) 2018-08-31
US20180099949A1 (en) 2018-04-12
US10717725B2 (en) 2020-07-21
RS57170B1 (sr) 2018-07-31
DK3140296T3 (en) 2018-07-23
SMT201800342T1 (it) 2018-09-13
CN106458976A (zh) 2017-02-22
CN106458976B (zh) 2020-05-22
EA033250B1 (ru) 2019-09-30
CY1120340T1 (el) 2019-07-10
EA201692037A1 (ru) 2017-06-30
TN2016000444A1 (en) 2018-04-04
PH12016502034B1 (en) 2022-03-23
ES2674531T3 (es) 2018-07-02
CL2016002809A1 (es) 2017-03-24
KR20160147049A (ko) 2016-12-21
TW201625585A (zh) 2016-07-16
IL248668B (en) 2019-09-26
IL248668A0 (en) 2017-01-31
MX2016013801A (es) 2017-03-09
SG11201609170UA (en) 2016-12-29
MA39427B1 (fr) 2018-09-28
EP3140296A1 (en) 2017-03-15
TR201809633T4 (tr) 2018-07-23
PE20161363A1 (es) 2016-12-17

Similar Documents

Publication Publication Date Title
HUS2100037I1 (hu) Vegyületek gerinc eredetû izomsorvadás kezelésére
IL248668B (en) Pyrrolidine gpr40 modulators for the treatment of diseases such as diabetes
EP3212233A4 (en) Combination therapy for treatment of disease
EP3227330A4 (en) Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
ZA201703112B (en) Substituted benzothiophenyl derivatives as gpr40 agonists for the treatment of type ii diabetes
EP3115012A4 (en) Treatment instrument for endoscope
IL249502B (en) New therapeutic uses of benzylideneguanidine derivatives for the treatment of diseases caused by structurally abnormal proteins
SMT202100082T1 (it) Composti eteroarilici per il trattamento di malattie oftalmiche
SG11201705194XA (en) Pharmaceutical composition for treating diabetes
IL270199A (en) Peptides for the treatment of diabetes
IL248670A0 (en) Pyrrolidine gpr40 modulators for the treatment of diseases such as diabetes
HUE070257T2 (hu) Vegyületek a lipofuscinhoz kapcsolódó betegségek kezelésére
EP3096775A4 (en) Socs mimetics for the treatment of diseases
GB201403996D0 (en) Traditional chinese medicine composition for the treatment of diabetes
EP3145525A4 (en) Use of microperoxidases for the treatment of carboxyhemoglobinemia
ZA201804588B (en) Pharmaceutical formulations for the treatment of diabetes
SG11201703330YA (en) Iminosugars useful for the treatment of viral diseases
EP3184055A4 (en) Medical treatment instrument
HUE060927T2 (hu) N,N-bisz-2-merkaptoetil-izoftálamid neurodegeneratív betegségek kezelésére
PT3166604T (pt) Agentes para o tratamento de doenças infeciosas retrovirais
AU2015904246A0 (en) Treatment of diabetes
AU2016901862A0 (en) Treatment of diabetes
HK1238246A1 (en) Iminosugars useful for the treatment of viral diseases
HK1238246A (en) Iminosugars useful for the treatment of viral diseases